These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900 [TBL] [Abstract][Full Text] [Related]
3. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849 [TBL] [Abstract][Full Text] [Related]
4. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Faber AC; Coffee EM; Costa C; Dastur A; Ebi H; Hata AN; Yeo AT; Edelman EJ; Song Y; Tam AT; Boisvert JL; Milano RJ; Roper J; Kodack DP; Jain RK; Corcoran RB; Rivera MN; Ramaswamy S; Hung KE; Benes CH; Engelman JA Cancer Discov; 2014 Jan; 4(1):42-52. PubMed ID: 24163374 [TBL] [Abstract][Full Text] [Related]
5. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847 [TBL] [Abstract][Full Text] [Related]
6. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909 [TBL] [Abstract][Full Text] [Related]
7. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation. Al-Salama ZT Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242 [TBL] [Abstract][Full Text] [Related]
9. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716 [TBL] [Abstract][Full Text] [Related]
12. CRISPR screens identify a novel combination treatment targeting BCL-X Jung HR; Oh Y; Na D; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Jeong EM; An JY; Sung CO; Lee WS; Lee C; Cho SY Oncogene; 2021 May; 40(18):3287-3302. PubMed ID: 33846570 [TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017 [TBL] [Abstract][Full Text] [Related]
14. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. Kopetz S; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Belani A; Zhang X; Tabernero J ESMO Open; 2022 Jun; 7(3):100477. PubMed ID: 35653981 [TBL] [Abstract][Full Text] [Related]
15. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. Tabernero J; Velez L; Trevino TL; Grothey A; Yaeger R; Van Cutsem E; Wasan H; Desai J; Ciardiello F; Yoshino T; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S ESMO Open; 2021 Dec; 6(6):100328. PubMed ID: 34896698 [TBL] [Abstract][Full Text] [Related]
16. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976 [TBL] [Abstract][Full Text] [Related]
18. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320 [TBL] [Abstract][Full Text] [Related]
19. 5-FU preferably induces apoptosis in BRAF V600E colorectal cancer cells via downregulation of Bcl-x Shi T; Gao M; He M; Yue F; Zhao Y; Sun M; He K; Chen L Mol Cell Biochem; 2019 Nov; 461(1-2):151-158. PubMed ID: 31352611 [TBL] [Abstract][Full Text] [Related]
20. Combination Treatment with the BRAF Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]